Trial: 202105159

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkins Lymphoma or Multiple Myeloma

Phase

I/II (Cancer Control)

Principal Investigator

Mehta-Shah, Neha

Disease Site

Multiple Myeloma; Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov